PRLD vs. CGEN, LRMR, CTNM, AMRN, OGI, OCGN, VIRI, ZYBT, MOLN, and INMB
Should you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Compugen (CGEN), Larimar Therapeutics (LRMR), Contineum Therapeutics (CTNM), Amarin (AMRN), Organigram (OGI), Ocugen (OCGN), Virios Therapeutics (VIRI), Zhengye Biotechnology (ZYBT), Molecular Partners (MOLN), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry.
Prelude Therapeutics vs.
Compugen (NASDAQ:CGEN) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment.
Compugen has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500.
Compugen currently has a consensus target price of $4.00, suggesting a potential upside of 88.24%. Prelude Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 354.55%. Given Prelude Therapeutics' higher probable upside, analysts clearly believe Prelude Therapeutics is more favorable than Compugen.
12.2% of Compugen shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 62.8% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Compugen had 4 more articles in the media than Prelude Therapeutics. MarketBeat recorded 5 mentions for Compugen and 1 mentions for Prelude Therapeutics. Compugen's average media sentiment score of 0.55 beat Prelude Therapeutics' score of 0.00 indicating that Compugen is being referred to more favorably in the media.
Compugen has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.
Compugen has a net margin of 2.67% compared to Prelude Therapeutics' net margin of 0.00%. Compugen's return on equity of 2.62% beat Prelude Therapeutics' return on equity.
Compugen received 279 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 64.38% of users gave Compugen an outperform vote while only 49.18% of users gave Prelude Therapeutics an outperform vote.
Summary
Compugen beats Prelude Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Prelude Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prelude Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PRLD) was last updated on 2/21/2025 by MarketBeat.com Staff
Free PRLD Stock Alerts